FDA Panel Votes to Recommend 6 of 7 Peptides for Compounding, Rejects DSIP
TL;DR: FDA's PCAC voted 23-24 Jul 2026 to back 6 of 7 peptides for compounding, incl. BPC-157 & TB-500; only DSIP was rejected.
What Happened on Day One of the PCAC Hearing?
The FDA's Pharmacy Compounding Advisory Committee met at the agency's White Oak campus on 23–24 July 2026 to decide whether seven peptides — previewed in our earlier coverage of the hearing agenda — should be recommended for the Section 503A Bulk Drug Substances Category 1 list. On day one, the committee voted on BPC-157, KPV and TB-500 together, clearing all three by an 8–6 margin with one abstention, according to reporting from STAT News and ABC News.[1][2] MOTS-c followed with a narrower result — 7 in favour, 5 against, 2 abstentions — per trade-press coverage of the same session.[3]
Trade publication The FDA Law Blog described the outcome as something the committee had never done before: over the course of a single day, it voted to recommend that compounding pharmacies be permitted to prepare all four peptides in front of it.[3] STAT News framed the BPC-157 and KPV result specifically as a win for the peptides' advocates inside the Department of Health and Human Services, given the committee's decision ran directly counter to the FDA's own scientific staff review.[1]
Which Peptides Were Recommended, and Which Was Rejected?
Day two, on 24 July, covered the remaining three peptides. Semax was recommended 8–5 and Epitalon 7–4. DSIP — listed in the FDA docket under its INN, emideltide — was the one peptide the committee voted down, narrowly, 6–7.[4] Across both days, six of the seven peptides under review received a favourable recommendation; DSIP was the sole rejection.
| Peptide | Day | Vote (yes–no, abstain) | Outcome |
|---|---|---|---|
| BPC-157 | 23 Jul | 8–6, 1 abstain | Recommended |
| KPV | 23 Jul | 8–6, 1 abstain | Recommended |
| TB-500 | 23 Jul | 8–6, 1 abstain | Recommended |
| MOTS-c | 23 Jul | 7–5, 2 abstain | Recommended |
| Semax | 24 Jul | 8–5 | Recommended |
| Epitalon | 24 Jul | 7–4 | Recommended |
| DSIP (emideltide) | 24 Jul | 6–7 | Rejected |
Vote tallies as reported by cited trade and health press; the FDA has not published an official tally sheet as of this writing.
Why Did FDA Staff Oppose a Vote the Committee Backed?
The result is notable mainly because of who opposed it. As our earlier coverage of the FDA's own scientific review detailed, the agency's career scientists posted a briefing document ahead of the meeting recommending against adding any of the seven peptides to the bulks list, citing thin human safety and efficacy data. The committee went the other way on six of seven.
Committee composition is part of the story. Eight of the panel's voting members were newly appointed as temporary members on 29 June 2026, drawn from fields including clinical research, neurology, gastroenterology, pain management and patient advocacy. Separately, pre-hearing reporting raised conflict-of-interest questions about some of the committee's other members, citing financial ties to clinics and pharmacies that sell peptide products — concerns the FDA itself reportedly flagged while assembling the panel.[5]
None of this changes what the vote actually is: a recommendation, not a rule. It does mean the numbers above should be read as one advisory committee's judgment call under public scrutiny, not as a settled scientific conclusion about any of these seven compounds.
Does a PCAC Recommendation Change Anything Yet?
No, not immediately. As covered in our reporting on the public comment docket, a PCAC vote is advisory only. The FDA independently reviews the committee's recommendation and the docket comments, then decides whether to open formal notice-and-comment rulemaking to add any of the six recommended peptides to the Section 503A Bulk Drug Substances Category 1 list. That rulemaking process has its own timeline, separate from and slower than the two-day hearing itself, and the FDA is not obliged to follow the committee's recommendation at all.
| Step | Status as of 25 July 2026 |
|---|---|
| PCAC hearing & vote | Complete (23–24 Jul) — advisory recommendation only |
| FDA review of recommendation | Pending — no fixed timeline published |
| FDA rulemaking decision | Not started; separate step from the vote itself |
| 503A compounding pathway live for any of the 6 | Not yet — requires completed rulemaking |
It is also a US compounding-pharmacy mechanism specifically, distinct from full FDA drug approval. A compounded peptide dispensed under 503A is prepared by a licensed pharmacy against an individual prescription for a substance that has never gone through a New Drug Application. That is a different regulatory track entirely from a licensed pharmaceutical candidate such as retatrutide, which follows Eli Lilly's own NDA process and is separately targeting a Q1 2027 BLA submission after its Phase 3 TRIUMPH programme.
What Does the PCAC Vote Mean for UK Research-Peptide Buyers?
Nothing changes on this side of the Atlantic. The Section 503A Bulk Drug Substances List and the PCAC advisory process are US-specific mechanisms created under US federal law and FDA guidance. Neither this vote nor any subsequent FDA rulemaking alters the regulatory status of research peptides in the UK, which sits under the Human Medicines Regulations 2012 and MHRA guidance — see our guide on whether research peptides are legal in the UK.
The underlying activity is also different in kind. A US compounding pharmacy operating under a positive 503A determination would be preparing a product against an individual patient prescription. Velox Peptides supplies BPC-157, TB-500, KPV, MOTS-c, Semax and DSIP as HPLC-verified in vitro research reagents only — there is no prescription, no human dosing guidance and no health claim attached to any product we sell, regardless of how the FDA rulemaking process eventually resolves.
These compounds are supplied as research reagents only. They are not medicines and have not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- STAT News. FDA panel backs compounded BPC-157, KPV peptides in win for RFK Jr. 23 July 2026. statnews.com
- ABC News. FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list. 23 July 2026. abcnews.com
- The FDA Law Blog. PEPTIDE-L WAVE! PCAC Approves Four Bulk Drug Substances for the 503A List. 23 July 2026. thefdalawblog.com
- RAPS (Regulatory Affairs Professionals Society). FDA advisory committee backs two controversial peptides. 24 July 2026. raps.org
- Saving Advice (citing Washington Post reporting). FDA Peptide Advisory Panel Faces Questions About Members' Potential Conflicts of Interest. 22 July 2026. savingadvice.com
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Docket FDA-2025-N-6895. fda.gov
Frequently Asked Questions
What did the FDA's PCAC vote on 23-24 July 2026?
The Pharmacy Compounding Advisory Committee met at FDA's White Oak campus on 23-24 July 2026 to vote on whether seven peptides should be recommended for the Section 503A Bulk Drug Substances list. On day one (23 July) it voted in favour of BPC-157, KPV and TB-500 (8-6, one abstention) and MOTS-c (7-5, two abstentions). On day two (24 July) it voted in favour of Semax (8-5) and Epitalon (7-4), and rejected DSIP, also called emideltide (6-7).
Which peptides were recommended, and which was rejected?
Six of the seven peptides under review received a favourable PCAC recommendation: BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon. DSIP (emideltide) was the only one the committee voted down, by a narrow 6-7 margin.
Does a favourable PCAC vote mean BPC-157 and TB-500 are now legal to compound in the US?
No. The PCAC's recommendation is advisory only - the FDA is not legally required to follow it. Before any of these peptides could be added to the 503A Bulk Drug Substances list, the FDA must independently review the committee's recommendation and the public docket, then complete a formal notice-and-comment rulemaking process, which has no announced timeline.
Why did FDA staff oppose peptides the committee went on to recommend?
FDA's own scientific review, posted ahead of the meeting, recommended against adding any of the seven peptides to the bulks list, citing limited human safety and efficacy data. The committee that voted to recommend six of the seven included eight newly appointed temporary voting members added on 29 June 2026; some press reporting has raised conflict-of-interest questions about other committee members' financial ties to clinics and pharmacies that sell peptides.
Does the PCAC vote affect UK research-reagent supply?
No. The Section 503A Bulk Drug Substances List and the PCAC advisory process are US-specific mechanisms governed by US federal law. They have no bearing on the regulatory status of research peptides in the UK, which is governed by the Human Medicines Regulations 2012 and MHRA guidance. Velox Peptides supplies BPC-157, TB-500, KPV, MOTS-c, Semax and DSIP as HPLC-verified in vitro research reagents only, a status unchanged by this vote.